In relation to statin metabolism by CYP2C9 isoenzyme, Lin et al. have evaluated the associations of CYP2C9 genetic polymorphisms with the efficacy and safety of rosuvastatin in patients with hyperlipidemia. This evidence concerns the gene CYP2C9 and hyperlipidemia.